Media ReleasesArovella Therapeutics

View All Arovella Therapeutics News

Arovella Therapeutics - R&D Tax Incentive refund received

Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray delivery technology to treat cancer and conditions that affect the central nervous system, is pleased to advise that it has received a refund of $524,042 from the Australian Taxation Office under the R&D Tax Incentive for the 2021 financial year.

The incentive recognises the research and development activities undertaken by Arovella during the last financial year. The receipt of $0.52m in additional funding will further support Arovella’s development work for the current year.

The Australian government’s R&D tax incentive encourages companies to engage in R&D programs by providing a refundable tax offset of up to 43.5% for eligible activities.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.